Objective  To explore the pharmacological mechanism of Sinisan when using the same treatment to treat different diseases such as liver cancer, chronic hepatitis, fatty liver and Hashimoto's thy-roiditis, based on the published network pharmacology research.

Methods  The network pharmacology research for Sinisan was retrieved and Sinisan’s active ingredients, targets and pathways corresponding to various diseases were extracted. A Microsoft Excel table was used to draw the Chinese medicine-disease component table, target-disease table, pathway-disease table and carry out descriptive analysis.

Results  A total of 20 studies on Sinisan's network pharmacology were included. There were 244 active ingredients corresponding to 14 diseases in 4 Chinese herbal medicines. The top 10 active ingredients were kaempferol, isorhamnetin, quercetin, paeoniflorin, formononetin, naringenin, isoflavone, shiitake mushroom, flavo-noids, and solanine. There were 243 corresponding targets and 395 pathways, among which VEGFA, IL-6, EGFR, CCND1, CASP3, STAT3, PPARG, ICAM1, FOS, CYP3A4 and other key targets played a role by reg-ulating important pathways such as the TNF signaling pathway, Tolllike receptor signaling pathway, PI3K-Akt signaling pathway, HIF-1 signaling pathway and membrane rafts pathway.

Conclusion  The research results show that Sinisan is efficacious for 14 diseases through multiple components, multiple tar-gets and multiple pathways. This study provides new clues for further exploring the mechanism of Sinisan's "Treating Different Diseases with the Same Treatment".

1.徐凌志, 李树波. 四逆散的神经系统药理作用与临床应用[J]. 长春中医药大学学报, 2010, 26(1): 126-127. [Xu LZ, Li SB. Pharmacological effects and clinical application of Sini powder in nervous system[J].Journal of Changchun University of Traditional Chinese Medicine, 2010, 26(1): 126-127.] DOI: 10.13463/j.cnki.cczyy.2010.01.069.

2.朱力阳, 彭成, 彭延娟. 四逆散治疗大鼠肝脾不调证肠易激综合征模型的研究[J]. 四川中医, 2010, 28(8): 10-12. [Zhu LY, Peng C, Peng YJ. Study on Sini Powder in the treatment of irritable bowel syndrome in rats with liver and spleen disorders[J]. Sichuan Traditional Chinese Medicine, 2010, 28(8): 10-12.] DOI: CNKI:SUN:SCZY.0.2010-08-007.

3.张霞, 张芳, 赵建军, 等. 甘草中黄酮类化合物的网络药理学研究[J]. 中国药房, 2019, 30(11): 1529-1534. [Zhang X, Zhang F, Zhao JJ, et al. Research on network pharmacology of flavonoids from glycyrrhiza uralensis[J]. China Pharmacy, 2019, 30(11): 1529-1534.] DOI: 10.6039/j.issn.1001-0408.2019.11.18.

4.侯雪楠, 张苗, 崔赛男, 等. 基于网络药理学探讨四逆散“一方多效”的分子机制[J]. 新中医, 2020, 52(11): 26-31. [Hou XN, Zhang M, Cui SN, et al. Exploring the molecular mechanism of "one side with multiple effects" of Sini Powder based on network pharmacology[J]. Journal of New Chinese Medicine, 2020, 52(11): 26-31.] DOI: 10.13457/j.cnki.jncm.2020.11.007.

5.世界中医药学会联合会. 网络药理学评价方法指南[J]. 世界中医药, 2021, 16(4): 527-532. [World Federation of Traditional Chinese Medicine Societies. Guidelines for evaluation methods of network pharmacology[J]. World Chinese Medicine, 2021, 16(4): 527-532.] DOI: 10.3969/j.issn.1673-7202.2021.04.001.

6.李菁, 莫嘉浩, 许洪彬, 等. 基于网络药理学与分子对接研究四逆散治疗肝癌的作用机制[J]. 临床肝胆病杂志, 2020, 36(9): 1998-2004. [Li J, Mo JH, Xu HB, et al. Study on the mechanism of Sini powder in the treatment of liver cancer based on network pharmacology and molecular docking[J]. Journal of Clinical Hepatology, 2020, 36(9): 1998-2004.] DOI: 10.3969/j.issn.1001-5256.2020.09.018.

7.杜金鑫, 杨士伟, 辛学知. 基于GEO差异分析及网络药理学的四逆散治疗溃疡性结肠炎作用机制研究[J].中国现代中药, 2021, 23(4): 645-654. [Du JX, Yang SW, Xin XZ. Study on the mechanism of Sini powder in the treatment of ulcerative colitis based on GEO difference analysis and network pharmacology[J]. Modern Chinese Medicine, 2021, 23(4): 645-654.] DOI: 10.13313/j.issn.1673-4890.20200529008.

8.李佳容, 邓海霞, 陈更新. 基于关键靶点及相关信号通路分析的四逆散治疗肠易激综合征分子作用机制的研究[J]. 湖南中医药大学学报, 2021, 41(11): 1737-1744. [Li JR, Deng HX, Chen GX. Molecular mechanism of Sini powder in the treatment of irritable bowel syndrome based on analysis of key targets and related sig-naling pathways[J]. Journal of Traditional Chinese Medicine University of Hunan, 2021, 41(11): 1737-1744.] DOI: 10.3969/j.issn.1674-070X.2021.11.015.

9.冯贺龙, 王晓雪, 张福利. 基于网络药理学的四逆散保肝作用机制研究[J]. 中草药, 2020, 51(24): 6258-6268. [Feng HL, Wang XX, Zhang FL. Study on the mechanism of Sini powder on liver protection based on network pharmacology[J]. Chinese Herbal Medicine, 2020, 51(24): 6258-6268.] DOI: 10.7501/j.issn.0253-2670.2020.24.015.

10.刘梦, 吴凤芝, 张蔚, 等. 基于网络药理学的四逆散与酸枣仁汤治疗失眠分子机制的比较研究[J]. 北京中医药大学学报, 2019, 42(1): 44-51. [Liu M, Wu FZ, Zhang W, et al. A comparative study on the molecular mechanism of Sini powder and Suanzaoren decoction in the treatment of insomnia based on network pharmacolo-gy[J]. Journal of Beijing University of Traditional Chinese Medicine, 2019, 42(1): 44-51.] DOI: 10.3969/j.issn.1006-2157.2019.01. 008.

11.卢鑫,张馨月,林逸婷,等.基于网络药理学—分子对接探讨四逆散“异病同治”溃疡性结肠炎和肠易激综合征的作用机制[J/OL]. 中药药理与临床: 1-25[2022-03-31]. [Lu X, Zhang XY, Lin YT, et al. Based on network pharma-cology-molecular docking to explore the mechanism of Sini San's "similar disease and same treatment" in ulcerative colitis and irritable bowel syndrome[J/OL]. Chinese Medicine Pharmacology and Clinical: 1-25[2022-03-31].] DOI: 10.13412/j.cnki.zyyl.20210806.010.

12.宗阳, 陈婷, 董宏利, 等. 基于网络药理学四逆散治疗抑郁症的作用机制探讨[J]. 中草药, 2019, 50(20): 4995-5002. [Zong Y, Chen T, Dong HL, et al. Discussion on the mechanism of action of Sini Powder in the treat-ment of depression based on network pharmacology[J]. Chinese Traditional and Herbal Drugs, 2019, 50(20): 4995-5002.] DOI: 10.7501/j.issn.0253-2670.2019.20.022.

13.严海冬, 缪文清, 张志鹏, 等. 基于网络药理学探讨四逆散治疗肠易激综合征的潜在作用机制[J]. 广东药科大学学报, 2021, 37(3): 59-65. [Yan HD, Miao WQ, Zhang ZP, et al. To explore the potential mechanism of Sini powder in the treatment of irritable bowel syndrome based on network pharmacology[J]. Journal of Guangdong Pharmaceutical University, 2021, 37(3): 59-65.] DOI: 10.16809/j.cnki.2096-3653.2020110308.

14.毕艺鸣, 殷贝, 夏亚情, 等. 基于网络药理学探讨四逆散治疗2型糖尿病的作用机制[J]. 中国实验方剂学杂志, 2020, 26(24): 169-177. [Bi YM, Yin B, Xia YQ, et al. The mechanism of action of Sini powder in the treatment of type 2 diabetes based on network pharmacology[J]. Chinese Journal of Experimental Prescriptions, 2020, 26(24): 169-177.] DOI: 10.13422/j.cnki.syfjx.20202060.

15.王惠临, 张立平. 基于网络药理学探讨四逆散治疗功能性消化不良的作用机制[J]. 世界中医药, 2021, 16(10): 1507-1513. [Wang HL, Zhang LP. The mechanism of action of Sini powder in the treatment of function-al dyspepsia based on network pharmacology[J]. World Chinese Medicine, 2021,16(10): 1507-1513.] DOI: 10.3969/j.issn.1673-7202.2021.10.002.

16.李硕, 李小科, 甘大楠, 等. 基于网络药理学探讨四逆散治疗慢性乙型肝炎的作用机制[J]. 中西医结合肝病杂志, 2021, 31(2): 108-113. [Li S, Li XK, Gan DN, et al. The mechanism of action of Sini powder in the treatment of chronic hepatitis B based on network pharmacology[J]. Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases, 2021, 31(2): 108-113.] DOI: 10.3969/j.issn.1005-0264.2021.02.003.

17.肖瑶, 李俊, 魏军平. 基于网络药理学探讨四逆散治疗桥本甲状腺炎作用机制[J]. 北京中医药, 2021, 40(6): 655-659. [Xiao Y, Li J, Wei JP. Discussion on the mechanism of Sini Powder in the treatment of Hashimoto's thy-roiditis based on network pharmacology[J]. Beijing Chinese Medicine, 2021, 40(6): 655-659.] DOI: 10.16025/j.1674-1307.2021.06.026.

18.侯磊, 李晓宇, 黄娜娜, 等. 四逆散干预焦虑症作用机制的网络药理学分析[J]. 中草药, 2019, 50(21): 5154-5161. [Hou L, Li XY, Huang NN, et al. A network pharmacological analysis of the mechanism of Sini powder intervening in anxiety disorders[J]. Chinese Traditional and Herbal Drugs, 2019, 50(21): 5154-5161.] DOI: 10.7501/j.issn.0253-2670.2019.21.004.

19.王慧慧, 张百霞, 叶小彤, 等. 基于“中药作用机理辅助解析系统”的四逆散抗抑郁作用机制研究[J].中国中药杂志, 2015, 40(19): 3723-3728. [Wang HH, Zhang BX, Ye XT, et al. Study on the antidepressant mechanism of Sini powder based on the "aided analysis system of the action mechanism of traditional Chinese medi-cine"[J]. China Journal of Chinese Materia Medica, 2015, 40(19): 3723-3728.] DOI: 10.4268/cjcmm20151906.

20.徐甜, 樊姝宁, 邓楠, 等. 基于分子网络研究四逆散抗抑郁症作用的潜在生物学机制[J]. 药物评价研究, 2019, 42(9): 1723-1729. [Xu T, Fan SN, Deng N, et al. Study on the potential biological mechanism of Sinisan's anti-depressant effect based on molecular network[J]. Drug Evaluation Research, 2019, 42(9): 1723-1729.] DOI: 10.7501/j.issn.1674-6376.2019.09.004.

21.Shu Z, He W, Shahen M, et al. Clarifying of the potential mechanism of Sinisan formula for treatment of chronic hepatitis by systems pharmacology method[J]. Biomed Pharmacother, 2018, 100: 532-550. DOI: 10.1016/j. biopha.2018.02.047.

22.Zhang Q, Feng Z, Gao M, et al. Determining novel candidate anti-hepatocellular carcinoma drugs using interaction networks and molecular docking between drug targets and natural compounds of SiNiSan[J]. PeerJ, 2021, 9: e10745. DOI: 10.7717/peerj.10745.

23.Wei X, Hou W, Liang J, et al. Network Pharmacology-based analysis on the potential biological mecha-nisms of Sinisan against non-alcoholic fatty liver disease[J]. Front Pharmacol, 2021, 12: 693701. DOI: 10.3389/fphar. 2021.693701.

24.Shen X, Zhao Z, Luo X, et al. Systems pharmacology based study of the molecular mechanism of SiNiSan formula for application in nervous and mental diseases[J]. Evid Based Complement Alternat Med, 2016, 2016: 9146378. DOI: 10.1155/2016/9146378.

25.He X, Wang N , Li Z , et al. Network pharmacology and GEO database-based analysis of Sini powder in the prevention of depression among shift workers[J]. All life, 2021, 15(1): 74-87. DOI: 10.1080/26895293.2021. 2019130.

26.郭盛楠, 周莉, 朱文浩, 等. 近20年异病同治相关研究述评[J]. 中国中医药信息杂志, 2014, 21(6): 129-131. [Guo SN, Zhou L, Zhu WH, et al. Review of related research on the same treatment of different diseases in the past 20 years[J]. Chinese Journal of Information on Traditional Chinese Medicine, 2014, 21(6): 129-131.] DOI: 10.3969/j.issn.1005-5304.2014.06.045.

27.谢宇霞, 皮明钧. 从临床流行病学调查探讨肝气郁结病机特点[J]. 中国中医药信息杂志, 2009, 16(12): 18-20. [Xie YX, Pi MJ. Discussion on the pathogenesis characteristics of liver-qi stagnation from clinical epidemiological investigation[J]. Chinese Journal of Information on Traditional Chinese Medicine, 2009, 16(12): 18-20.] DOI: 10.3969/j.issn.1005-5304.2009. 12.009.

28.胡倩, 刘大会, 曹艳. 艾叶黄酮类化合物的研究进展[J]. 食品安全质量检测学报, 2019, 10(12): 3648-3653. [Hu Q, Liu DH, Cao Y. Research progress on flavonoids of argyi leaves[J]. Journal of Food Safety & Quality, 2019, 10(12): 3648-3653.] DOI: 10.3969/j.issn.2095-0381.2019. 12.002.

29.Huang CH, Jan RL, Kuo CH, et al. Natural flavone kaempferol suppresses chemokines expression in human monocyte THP-1 cells through MAPK pathways[J]. J Food Sci, 2010, 75(8): H254-H259. DOI: 10.1111/j.1750-3841. 2010.01812.x.

30.Rehman K, Akash MSH, Liaqat A, et al. Role of interleukin-6 in development of insulin resistance and type 2 diabetes mellitus[J]. Crit Rev Eukaryot Gene Expr, 2017, 27(3): 229-236. DOI: 10.1615/CritRevEukaryotGeneExpr.2017019712.

31.郝日礼, 李大鹏. 酚类化合物干预镉致肝损伤的研究进展[J].食品科学, 2020, 41(9): 254-262. [Hao RL, Li DP. Re-cent progress in understanding the protective effect of phenolics against cadmium-induced liver inju-ry[J]. Food Science, 2020, 41(9): 254-262.] DOI: 10.7506/spkx1002-6630-20190425-334.

32.夏小雯, 孙亚, 宋春红, 等. 芍药苷抗抑郁的相关研究进展[J]. 世界科学技术-中医药现代化, 2019, 21(5): 912-917. [Xia XW, Sun Y, Song CH, et al. Relevant research progress of paeoniflorin for antidepressant[J].World Science and Technology-Modernization of Traditional Chinese Medicine, 2019, 21(5): 912-917.] DOI: 10.11842/wst.2019.05.012.

33.Dou W, Zhang J, Li H, et al. Plant flavonol isorhamnetin attenuates chemically induced inflammatory bowel disease via a PXR-dependent pathway[J]. J Nutr Biochem, 2014, 25(9): 923-933. DOI: 10.1016/j.jnutbio.2014.04.006.

34.田心, 常盼, 周亚光, 等. 刺芒柄花素对高糖诱导的小鼠系膜细胞炎症因子调控及增殖的影响[J]. 中成药, 2017, 39(5): 1052-1056. [Tian X, Chang P, Zhou YG, et al. Effects of formononetin on the regulation and proliferation of inflammatory factors in mouse mesangial cells induced by high glucose[J]. Chinese Traditional Patent Medicine, 2017, 39(5): 1052-1056.] DOI: 10.3969/j.issn.1001-1528.2017.05.036.

35.Fathy SA, Mohamed MR, Ali MAM, et al. Influence of IL-6, IL-10, IFN-γ and TNF-α genetic variants on susceptibility to diabetic kidney disease in type 2 diabetes mellitus patients[J]. Biomarkers, 2019, 24(1): 43-55. DOI: 10.1080/1354750X.2018.1501761.

36.李清韵,谢慧,李宇思,等.基于网络药理学和分子对接技术研究柴胡-黄芩药对治疗鼻窦炎的作用机制[J].中国比较医学杂志, 2021, 31(4): 44-54. [Li QY, Xie H, Li YS, et al. Study on the mechanism of bupleurum-scutellaria bai-calensis on the treatment of sinusitis based on network pharmacology and molecular docking tech-nology[J]. Chinese Journal of Comparative Medicine, 2021, 31(4): 44-54.] DOI: 10.3969/j.issn.1671-7856. 2021.04.008.

37.Siemińska L, Wojciechowska C, Kos-Kudła B, et al. Serum concentrations of leptin, adiponectin, and inter-leukin-6 in postmenopausal women with Hashimoto's thyroiditis[J]. Endokrynol Pol, 2010, 61(1): 112-116. DOI: 10.1080/1354750X.2018.1501761.

38.仝雪薇, 冶学燕, 刘春燕, 等. 2型糖尿病合并肥胖患者外周血PPARG、CIDEA、ECHDC3、CGN mRNA表达与血脂水平的关系研究[J]. 深圳中西医结合杂志, 2021, 31(6): 4-8, 199. [Tong XW, Ye XY, Liu CY, et al. Relationship between peripheral blood PPARG, CIDEA, ECHDC3, CGN mRNA expression and blood lipid levels in pa-tients with type 2 diabetes mellitus complicated by obesity[J]. Shenzhen Journal of Integrative Medicine, 2021, 31(6): 4-8, 199.] DOI: 10.16458/j.cnki.1007-0893. 2021.06.002.

39.Hashemian L, Sarhangi N, Afshari M, et al. The role of the PPARG (Pro12Ala) common genetic variant on type 2 diabetes mellitus risk[J]. J Diabetes Metab Disord, 2021, 20(2): 1385-1390. DOI: 10.1007/s40200-021-00872-6.

40.Yin Y, Yuan H, Wang C, et al. 3-phosphoinositide-dependent protein kinase-1 activates the peroxisome proliferator-activated receptor-gamma and promotes adipocyte differentiation[J]. Mol Endocrinol, 2006, 20(2): 268-278. DOI: 10.1210/me.2005-0197.

41.马晓宇,马玉,孙明军.基于数据挖掘分析结直肠癌组织VEGFA表达和意义[J]. 中华肿瘤防治杂志, 2021, 28(16): 1209-1214. [Ma XY, Ma Y, Sun MJ. Analysis of VEGFA expression and significance in colorectal cancer tissues based on data mining[J]. Chinese Journal of Cancer Prevention and Treatment, 2021, 28(16): 1209-1214.] DOI: 10.16073/j.cnki.cjcpt.2021.16.03.

42.刘传梦, 方静, 王元霞, 等. 中草药相关肝损伤机制研究进展[J]. 中华中医药学刊, 2020, 38(6): 177-181. [Liu CM, Fang J, Wang YX, et al. Research progress on the mechanism of Chinese herbal medicine-related liver injury[J]. Zhonghua Journal of Traditional Chinese Medicine, 2020, 38(6): 177-181.] DOI: 10.13193/j.issn. 1673-7717.2020.06.042.

43.依沙兰, 陈红, 邓永东, 等. 肿瘤坏死因子β基因多态性与乙肝后肝纤维化的相关性研究[J]. 第四军医大学学报, 2008, 29(1): 36-39. [Yi SL, Chen H, Deng YD, et al. Association between tumor necrosis factor beta gene poly-morphism and liver fibrosis after hepatitis B[J]. Journal of Fourth Military Medical University, 2008, (1): 36-39.] DOI: 10.3321/j.issn:1000-2790.2008.01.012.

44.Hu X, Tang J, Zeng G, et al. RGS1 silencing inhibits the inflammatory response and angiogenesis in rheumatoid arthritis rats through the inactivation of Toll-like receptor signaling pathway[J]. Cell Physiol, 2019, 234(11): 20432-20442. DOI: 10.1002/jcp.28645.

45.钟佳琳,郑立,贺花,等. PI3K/Akt信号通路相关的生物学调控机制研究进展[J]. 基因组学与应用生物学, 2019, 38(1): 143-147. [Zhong JL, Zheng L, He H, et al. Research progress on biological regulatory mechanisms re-lated to PI3K/Akt signaling pathway[J]. Genomics and Applied Biology, 2019, 38(1): 143-147.] DOI: 10.13417/j.gab.038.000143.

46.Balamurugan K. HIF-1 at the crossroads of hypoxia, inflammation, and cancer[J]. Int J Cancer, 2016, 138(5): 1058-1066. DOI: 10.1002/ijc.29519.

47.Zuo L, Wijegunawardana D. Redox role of ROS and inflammation in pulmonary diseases[J]. Adv Exp Med Biol, 2021, 1304: 187-204. DOI: 10.1007/978-3-030-68748-9_11.